secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immix Biopharma, Inc. (IMMX)
CIK:        0001873835
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0001641172-25-016120
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Immix Biopharma stockholders elect 8 directors and ratify Crowe LLP as 2025 auditor
--------------------------------------------------------------------------------

- All 8 director nominees elected with 'for' votes ranging from 13.4M to 14.6M; broker non-votes 5.5M across all director proposals.
- Ratification of Crowe LLP as independent auditor approved with 19.9M for, 47.6K against, 98.4K abstentions (no broker non-votes).
- 72.1% of outstanding shares (20.1M) were present or represented at the June 20, 2025 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873835/000164117225016120/0001641172-25-016120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873835/000164117225016120/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-016120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer